论文部分内容阅读
目的:评价保妇康栓与重组人干扰素-α2a栓对宫颈糜烂患者伴人乳头状瘤病毒(HPV)感染的临床疗效。方法:选取2014年2月—2016年2月间收治的106例宫颈糜烂伴HPV感染患者106例,根据住院顺序将其分为治疗组和对照组,每组53例;对照组患者给予保妇康栓外用治疗,治疗组患者在对照组基础上加用重组人干扰素-α2a栓治疗,对比两组患者治疗后的总有效率和不良反应的发生率。结果:治疗组患者治疗后的总有效率为96.23%高于对照组为83.02%(P<0.05);总不良反应的发生率为7.55%低于对照组为18.87%(P<0.05)。结论:保妇康栓联合重组人干扰素-α2a栓对宫颈糜烂患者伴HPV感染的临床疗效优于单用保妇康栓外用的疗效。
Objective: To evaluate the clinical efficacy of Baofukang Suppository and recombinant human interferon-α2a suppository in patients with cervical erosion with human papillomavirus (HPV) infection. Methods: A total of 106 patients with cervical erosion and HPV infection who were treated between February 2014 and February 2016 were selected and divided into treatment group and control group according to hospitalization order, with 53 cases in each group. Kang external suppository treatment, the treatment group patients in the control group plus recombinant interferon-α2a suppository treatment, the two groups were compared after treatment, the total effective rate and the incidence of adverse reactions. Results: The total effective rate of the treatment group after treatment was 96.23% higher than that of the control group (83.02%, P <0.05). The incidence of the total adverse reaction was 7.55% lower than that of the control group (18.87%, P <0.05). Conclusion: Baofukang Suppository combined with recombinant human interferon-α2a suppository has better curative effect than HPV-Baoshuang Suppository alone in patients with cervical erosion.